Sera Prognostics (NASDAQ:SERA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.
According to Zacks, “Sera Prognostics Inc. is a women’s health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY. “
Other analysts also recently issued research reports about the stock. Berenberg Bank initiated coverage on shares of Sera Prognostics in a report on Wednesday, April 27th. They issued a “buy” rating on the stock. Citigroup downgraded shares of Sera Prognostics from a “buy” rating to a “neutral” rating in a report on Wednesday, March 30th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Sera Prognostics currently has an average rating of “Buy” and an average target price of $18.50.
Sera Prognostics (NASDAQ:SERA – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.08 million. Sera Prognostics had a negative net margin of 38,185.05% and a negative return on equity of 58.37%. On average, sell-side analysts anticipate that Sera Prognostics will post -1.5 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Skye Global Management LP boosted its holdings in Sera Prognostics by 5.6% during the fourth quarter. Skye Global Management LP now owns 376,000 shares of the company’s stock worth $2,583,000 after buying an additional 20,000 shares in the last quarter. BlackRock Inc. purchased a new stake in Sera Prognostics during the third quarter worth about $1,667,000. OUP Management Co. LLC purchased a new stake in Sera Prognostics during the fourth quarter worth about $4,406,000. Fosun International Ltd purchased a new stake in Sera Prognostics during the fourth quarter worth about $3,807,000. Finally, Tudor Investment Corp Et Al purchased a new stake in Sera Prognostics during the third quarter worth about $726,000. 63.20% of the stock is currently owned by hedge funds and other institutional investors.
Sera Prognostics Company Profile (Get Rating)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
- Get a free copy of the StockNews.com research report on Sera Prognostics (SERA)
- Chargepoint’s Stock Could Benefit from High Energy Prices
- Is It Too Late For Energy Stocks?
- MarketBeat Podcast: Get Your Mindset Right To Invest In The Current Market
- It’s Time To Get Interested In Ethereum Again
- Stratasys Stock Forming a Tradeable Bottom
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.